Medical Condition

follicular lymphoma

Total Trials

12

Recruiting Now

12

Trial Phases

Phase 2, Phase 1, Phase 1, Phase 2

Lymphoma trials span diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, Hodgkin lymphoma, mantle cell lymphoma, and T-cell lymphomas β€” each with distinct biology and treatment response. CAR-T cell therapy has established a new standard in relapsed/refractory DLBCL, and trials now aim to move this approach earlier in the treatment sequence.

Active trials evaluate bispecific antibodies (mosunetuzumab, epcoritamab, glofitamab), next-generation CAR-T cell products (CD19/CD22 dual targets, BCMA-targeting), BTK inhibitors in B-cell lymphomas, and total metabolic volume on PET as a predictive biomarker for treatment adaptation.

Frequently Asked Questions — follicular lymphoma Clinical Trials

How many clinical trials are currently recruiting for follicular lymphoma?

ClinicalMetric currently tracks 12 actively recruiting clinical trials for follicular lymphoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 12. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for follicular lymphoma?

follicular lymphoma research spans Phase 1 (5 trials), Phase 2 (3 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a follicular lymphoma clinical trial?

Eligibility criteria for follicular lymphoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

Phase 2

Top Sponsors

Institute of Hematology & Blood Diseases Hospital, China 2 trials

Masonic Cancer Center, University of Minnesota 1 trial

Newave Pharmaceutical Inc 1 trial

Paolo Corradini 1 trial

BeOne Medicines 1 trial

Recruiting Clinical Trials

NCT05805605 Phase 2

Recruiting

Allo HSCT Using RIC and PTCy for Hematological Diseases

Masonic Cancer Center, Univers...

View Trial →

NCT04775745 Phase 1

Recruiting

Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.

Newave Pharmaceutical Inc

View Trial →

NCT06339255

Recruiting

Italian Observational Study on CAR-T Therapy for Lymphoma

NCT05006716 Phase 1, Phase 2

Recruiting

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

Enrollment

645 pts

Location

United States, Austr...

A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing Setting

Juno Therapeutics, Inc., a Bri...

View Trial →

NCT05326308

Recruiting

Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma

IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas

Enrollment

140 pts

Location

United States, Austr...

Sponsor

Iksuda Therapeutics Ltd.

View Trial →

NCT05544019 Phase 1

Recruiting

Study of SGR-1505 in Mature B-Cell Neoplasms

Enrollment

98 pts

Location

United States, Franc...

Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

UNC Lineberger Comprehensive C...

View Trial →

NCT05541341

Recruiting

Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte Malignancies

Novartis Pharmaceuticals

View Trial →

NCT05846763

Recruiting

Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Follicular Lymphoma in Real World Study

Institute of Hematology & Bloo...

View Trial →

NCT07555470 Phase 2

Recruiting

Mosunetuzumab and Zeprumetostat in Treating Patients With Follicular Lymphoma

Institute of Hematology & Bloo...

View Trial →

Related Conditions

mantle cell lymphoma (6) marginal zone lymphoma (4) diffuse large b cell lymphoma (4) chronic lymphocytic leukemia (3) burkitt lymphoma (2) small lymphocytic lymphoma (2) waldenstrom macroglobulinemia (2) non hodgkin lymphoma (2) splenic marginal zone lymphoma (2) nodal marginal zone lymphoma (2) acute myelogenous leukemia (1) acute lymphocytic leukemia (1)

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology